Kaleido Biosciences to Present During the Goldman Sachs 41st Annual Global Healthcare Conference
June 04, 2020 08:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
June 01, 2020 21:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
June 01, 2020 16:17 ET
|
Kaleido Biosciences
LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
Kaleido Biosciences Provides Corporate Update and Reports First Quarter 2020 Financial Results
May 14, 2020 06:32 ET
|
Kaleido Biosciences
- Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 - - Expanding Work in Immune-Mediated and Inflammatory Diseases; Data from New...
Kaleido Biosciences Initiates Controlled Clinical Study of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19
May 14, 2020 06:30 ET
|
Kaleido Biosciences
- Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 - - Second Clinical Study Expected to Initiate Shortly with Similar Design and Additional Microbiome Analysis...
Kaleido Biosciences to Host Conference Call and Webcast in Conjunction with First Quarter 2020 Financial Results on May 14, 2020
May 12, 2020 08:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido Biosciences Appoints Anne Prener, M.D., Ph.D., to its Board of Directors
April 03, 2020 08:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido Biosciences to Present During Chardan’s 2nd Annual Microbiome Medicines Summit
March 10, 2020 08:30 ET
|
Kaleido Biosciences
LEXINGTON, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...
Kaleido Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 02, 2020 07:35 ET
|
Kaleido Biosciences
- Results from three clinical studies in 2019 support Phase 2 development program in urea cycle disorders (UCD) and advancement of hepatic encephalopathy program into next clinical study - Top-line...
Kaleido Biosciences Announces Collaboration with Janssen to Explore the Potential for Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions by Promoting Healthy Function of the Gut Microbiome
January 09, 2020 08:00 ET
|
Kaleido Biosciences
LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ...